Investigating the effect of human menopausal gonadotropin and human chorionic gonadotropin treatment on testicular biopsy results

Investigating the effect of human menopausal gonadotropin and human chorionic gonadotropin treatment on testicular biopsy results in Klinefelter patients.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N207

Enrollment

Registered

2023-08-20

Start date

2023-09-01

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male Infertility. Oligospermia

Interventions

Intervention 1: In the intervention group, HCG ampoules with a dose of 5000 units and HMG ampoules with a dose of 75 units are prescribed twice a week by intramuscular injection for 6 weeks. Intervent

Eligibility

Sex/Gender

Male

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Informed consent Age between 18 and 65 years Diagnosis of azoospermia based on semen analysis and urologist diagnosis Married patients

Exclusion criteria

Exclusion criteria: Any genetic disease other than Klinefelter that is associated with infertility Presence of any concomitant disease that leads to infertility, such as varicocele A history of infertility for any reason in the patient's wife The patient's single testicle

Design outcomes

Primary

Measure	Time frame
Presence and absence of sperm. Timepoint: The beginning of the study and the end of the study (6 weeks after the start of treatment). Method of measurement: Sperm test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Behrouz Rostami

Kermanshah University of Medical Sciences

Behrouzrostami1368@yahoo.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026